For the year ending 2025-12-31, IMDX has $25,756K in assets. $57,220K in debts. $11,583K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 11,583 | |||
| Accounts receivable, net of allowance for credit losses of 11 and 16, respectively | 1,128 | |||
| Inventories | 446 | |||
| Deferred financing costs | 0 | |||
| Restricted cash, current | 729 | |||
| Prepaid expenses and other current assets | 1,420 | |||
| Total current assets | 15,306 | |||
| Right-of-use operating and financing lease assets, net | 2,815 | |||
| Machinery and equipment, net, and construction in progress | 6,435 | |||
| Intangible assets, net | 0 | |||
| Restricted cash, noncurrent | 607 | |||
| Other noncurrent assets | 593 | |||
| Total assets | 25,756 | |||
| Accounts payable | 2,544 | |||
| Due to related party (note 9) | 2,780 | |||
| Accrued compensation | 2,461 | |||
| Accrued royalties | 1,116 | |||
| Accrued expenses and other current liabilities | 939 | |||
| Operating and financing lease liabilities, current | 1,807 | |||
| Contingent consideration liabilities, current | 428 | |||
| Total current liabilities | 12,075 | |||
| Operating and financing lease liabilities, noncurrent | 1,690 | |||
| Contingent consideration liabilities, noncurrent | 43,455 | |||
| Total liabilities | 57,220 | |||
| Preferred stock, no par value, 5,000 shares authorized no shares issued and outstanding | 0 | |||
| Common stock, no par value, 230,000 shares authorized 28,683 and 17,453 shares issued and outstanding at december 31, 2025 and 2024, respectively | 369,211 | |||
| Accumulated other comprehensive income | 86 | |||
| Accumulated deficit | -400,761 | |||
| Total shareholders' deficit | -31,464 | |||
| Total liabilities and shareholders' deficit | 25,756 | |||
Insight Molecular Diagnostics Inc. (IMDX)
Insight Molecular Diagnostics Inc. (IMDX)